3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Prostate Cancer
1
Mouth Neoplasms
1
Melanoma
1
Lung Diseases
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Cisplatin
20
Surgical Procedures, Operative
9
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
Specimen Handling
5
Radiotherapy
5
Fluorouracil
5
toripalimab
4
Surveys and Questionnaires
4
Radiation
4
Paclitaxel
4
Chemoradiotherapy
4
Celecoxib
4
X-Rays
3
Platinum
3
Counseling
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
camrelizumab
2
Taxes
2
Standard of Care
2
Psychiatric Rehabilitation
2
Practice Guidelines as Topic
2
Neoadjuvant Therapy
2
Narrow Band Imaging
2
Interviews as Topic
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hypopharyngeal Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn